SCHEDULE: Knoll Capital Management Discloses 5.3% Stake in Elicio Therapeutics

Knoll Capital Management, LLC, along with Fred Knoll and Gakasa Holdings, LLC, has reported beneficial ownership of 1,211,957 shares, representing 5.3% of Elicio Therapeutics, Inc.'s common stock.

Summary

• Knoll Capital Management, LLC, Fred Knoll, and Gakasa Holdings, LLC have jointly filed a Schedule 13G, indicating their beneficial ownership of 1,211,957 shares of Elicio Therapeutics, Inc. common stock.
• This holding represents 5.3% of the total class of securities.
• Knoll Capital Management has trading authority for Gakasa Holdings, and Fred Knoll serves as the President of Knoll Capital Management, LLC.
• The filing is an amendment to a previous filing, with the event date requiring this statement being July 1, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. It's a standard disclosure of ownership and does not provide new operational or financial information about Elicio Therapeutics itself.

Positives

• Significant stake of 5.3% in Elicio Therapeutics, Inc. by Knoll Capital Management and associated entities.
• Clear disclosure of beneficial ownership, providing transparency to the market.

Risks

• The filing does not explicitly detail any risks associated with this ownership stake.
• Potential for future changes in ownership or investment strategy by Knoll Capital Management could impact Elicio Therapeutics' stock.

Future Outlook

The filing itself does not contain forward-looking statements or guidance from Elicio Therapeutics. It is a disclosure of beneficial ownership by an investment entity.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors accumulating significant stakes in publicly traded companies. This filing indicates Knoll Capital Management's interest in Elicio Therapeutics, a biotechnology company, and its potential view on the company's future prospects.

Stakeholder Impact

• Shareholders: Increased transparency regarding significant ownership, potentially influencing market perception and trading activity.
• Elicio Therapeutics Management: Awareness of a substantial institutional investor's position.

Next Steps

• Continued monitoring of Elicio Therapeutics' performance and any further filings by Knoll Capital Management or other significant shareholders.

Key Dates

Keywords

Elicio Therapeutics, Schedule 13G, Knoll Capital Management, Gakasa Holdings, Fred Knoll, Beneficial Ownership, Common Stock, SEC Filing, Investment